Loading
Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer.
Richard Finn was principal investigator of PALOMA-2, the trial that established palbociclib plus letrozole as first-line therapy for HR-positive advanced breast cancer and launched the CDK4/6 inhibitor class. He then led IMbrave150, which showed atezolizumab plus bevacizumab beat sorafenib in unresectable hepatocellular carcinoma, ending a decade of sorafenib as the only option. His current work covers next-generation CDK inhibitors and immunotherapy sequencing in liver cancer.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, PD-L1 and the tag hcc.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares CDK4/6, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares the tags breast, trialist.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, Hepatocellular carcinoma.
Shares PD-L1, Hepatocellular carcinoma, Immune checkpoint inhibitors and the tags hcc, trialist.